Abstract | BACKGROUND: OBJECTIVE: METHODS: Ten patients with active plaque morphea were included. All patients were treated with tacrolimus 0.1% ointment and with an emollient ( petrolatum) on two selected morphea plaques, applied twice daily for 12 weeks. Initial and final assessment included surface area measurements, photography, durometer scores, and clinical feature scores. Adverse reactions were recorded. RESULTS: The scleroderma plaques treated with topical tacrolimus 0.1% improved, resulting in a significant reduction in durometer and clinical feature scores. Overall, a significant difference could be found between topical tacrolimus and petrolatum with regard to durometer score (p < 0.005) and the clinical feature score (p = 0.019). CONCLUSION:
|
Authors | Elisabeth B M Kroft, Tamara J Groeneveld, Marieke M B Seyger, Elke M G J de Jong |
Journal | American journal of clinical dermatology
(Am J Clin Dermatol)
Vol. 10
Issue 3
Pg. 181-7
( 2009)
ISSN: 1175-0561 [Print] New Zealand |
PMID | 19354332
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Emollients
- Immunosuppressive Agents
- Ointments
- Petrolatum
- Tacrolimus
|
Topics |
- Adult
- Aged
- Double-Blind Method
- Emollients
(therapeutic use)
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Ointments
(therapeutic use)
- Petrolatum
(therapeutic use)
- Pilot Projects
- Scleroderma, Localized
(diagnosis, drug therapy)
- Severity of Illness Index
- Tacrolimus
(therapeutic use)
- Treatment Outcome
- Young Adult
|